Literature DB >> 27073448

Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.

Qianqian Zhang1, Xiaolin Guo1, Shixing Zhao2, Xiaoli Pang1, Yang Wang1, Yujiao Zhang3, Baorong Chi1.   

Abstract

The present study aimed to analyze the prognostic factors of acute-on-chronic liver failure (ACLF), with the perspective of an improved selection of optimal therapeutic schemes. A retrospective analysis was used to study 164 patients with ACLF hospitalized between 2010 and 2014 in a single center. Patients were divided into favorable and unfavorable groups, according to the treatment outcomes. General characteristics and clinical manifestations were analyzed to determine whether they would affect the prognosis of the patients with ACLF, with a particular focus on the scoring systems Child-Pugh, model for end-stage liver disease (MELD), MELD with incorporation of sodium (MELD-Na), MELD and serum sodium ratio (MESO) and integrated MELD (iMELD). Hepatitis B virus infection was the predominant cause of ACLF, accounting for 88 cases (53.7%). Age, prothrombin time, thrombin time, international normalized ratio (INR), prothrombin activity, serum sodium, albumin, total bilirubin, serum creatinine, platelets, fasting blood sugar, infections, hepatic encephalopathy, hepatorenal syndrome (HRS), and electrolyte disorder were revealed to be associated with prognosis. Age, serum sodium, INR, HRS, and infection were independent prognostic risk factors, as determined by multivariate analysis. Child-Pugh, MELD, MELD-Na, MESO and iMELD scoring systems all demonstrated adequate predictive values, with MELD-Na as the most effective scoring system. In conclusion, age, hyponatremia, INR, HRS and bacterial or fungal infections were reported to be independent prognostic risk factors for ACLF. Among the various liver function scoring systems, MELD-Na was the most accurate in predicting the prognosis of ACLF.

Entities:  

Keywords:  acute-on-chronic liver failure; hepatic encephalopathy; hepatorenal syndrome; predictive value of tests; prognosis

Year:  2016        PMID: 27073448      PMCID: PMC4812404          DOI: 10.3892/etm.2016.3037

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

Review 1.  Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.

Authors:  Vicente Arroyo; Jordi Colmenero
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis.

Authors:  Angelo Luca; Berhard Angermayr; Guido Bertolini; Franz Koenig; Giovanni Vizzini; Martin Ploner; Markus Peck-Radosavljevic; Bruno Gridelli; Jaime Bosch
Journal:  Liver Transpl       Date:  2007-08       Impact factor: 5.799

Review 3.  Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis.

Authors:  R W Schrier; A K Gurevich; M A Cadnapaphornchai
Journal:  Semin Nephrol       Date:  2001-03       Impact factor: 5.299

4.  Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage.

Authors:  R Jalan; K Dabos; D N Redhead; A Lee; P C Hayes
Journal:  J Hepatol       Date:  1997-11       Impact factor: 25.083

5.  Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults.

Authors:  Yu Shi; Ying Yang; Yaoren Hu; Wei Wu; Qiao Yang; Min Zheng; Shun Zhang; Zhaojun Xu; Yihua Wu; Huadong Yan; Zhi Chen
Journal:  Hepatology       Date:  2015-04-25       Impact factor: 17.425

6.  Cerebral oedema and increased intracranial pressure in chronic liver disease.

Authors:  J P Donovan; D F Schafer; B W Shaw; M F Sorrell
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

7.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

8.  Predictors of the outcomes of acute-on-chronic hepatitis B liver failure.

Authors:  Hsiu-Lung Fan; Po-Sheng Yang; Hui-Wei Chen; Teng-Wei Chen; De-Chuan Chan; Chi-Hong Chu; Jyh-Cherng Yu; Shih-Ming Kuo; Chung-Bao Hsieh
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

9.  Efficacy of a chronic disease management model for patients with chronic liver failure.

Authors:  Alan J Wigg; Rosemary McCormick; Rachel Wundke; Richard J Woodman
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-29       Impact factor: 11.382

10.  Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure.

Authors:  Yun-Hao Xun; Jun-Ping Shi; Chun-Qing Li; Dan Li; Wei-Zhen Shi; Qing-Chun Pan; Jian-Chun Guo; Guo-Qing Zang
Journal:  Mol Med Rep       Date:  2014-02-25       Impact factor: 2.952

View more
  3 in total

1.  Prognostic factors of the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure.

Authors:  Qing Lei; Kangjian Ao; Yinhua Zhang; Deqiang Ma; Deping Ding; Changzheng Ke; Yue Chen; Jie Luo; Zhongji Meng
Journal:  Clinics (Sao Paulo)       Date:  2017-11       Impact factor: 2.365

2.  Acute-on-chronic liver failure: recent update.

Authors:  Azeem Alam; Ka Chun Suen; Daqing Ma
Journal:  J Biomed Res       Date:  2017-07-13

3.  Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure.

Authors:  Kessarin Thanapirom; Tongluk Teerasarntipan; Sombat Treeprasertsuk; Ashok Choudhury; Manoj K Sahu; Rakhi Maiwall; Viniyendra Pamecha; Richard Moreau; Mamun Al Mahtab; Yogesh Kumar Chawla; Harshad Devarbhavi; Chen Yu; Qin Ning; Deepak Amarapurkar; Chundamannil E Eapen; Saeed Sadiq Hamid; Amna Subhan Butt; Dong Joon Kim; Guan H Lee; Ajit Sood; Laurentious A Lesmana; Zaigham Abbas; Gamal Shiha; Diana A Payawal; Man-Fung Yuen; Albert Chan; George Lau; Jidong Jia; Salimur Rahman; Barjesh C Sharma; Osamu Yokosuka; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-11-25       Impact factor: 6.047

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.